Peptides for fat loss: what the evidence actually supports
Two peptides have strong, FDA-approved evidence for weight loss. Most of the rest are sold on hope. Here is how to tell the difference.

Educational only, not medical advice. Semaglutide and tirzepatide are FDA-approved prescription drugs. Retatrutide and CagriSema are investigational. AOD-9604, MOTS-c and 5-Amino-1MQ are not approved for any use. Doses mentioned come from published trials, not personal plans. Talk to a qualified healthcare provider before starting anything new.
The short answer
The peptides with real fat-loss evidence are the GLP-1 based drugs. They work mainly by reducing appetite, and they are prescription medicines, not supplements.
- Strongest evidence: tirzepatide and semaglutide, both FDA-approved, with large trials showing about 15% to 21% average weight loss.
- Coming next: retatrutide and CagriSema have strong late-stage results but are not approved yet.
- Weak evidence: AOD-9604, MOTS-c and 5-Amino-1MQ have little or no human fat-loss data.
- What decides long-term results: protecting muscle with training and protein, and planning for what happens if you stop.
How fat-loss peptides actually work
The effective ones copy hormones your gut already releases after a meal. They tell your brain you are full and slow how fast your stomach empties.
Semaglutide copies one hormone, GLP-1. Tirzepatide copies two, GLP-1 and GIP. Retatrutide adds a third, glucagon, which is studied for its effect on energy use. The result is that people eat less without relying on willpower alone.
None of them burn fat directly. Weight comes off because of a sustained calorie deficit, which is why diet quality and training still shape what that weight loss is made of.

The evidence ladder
Not all peptides marketed for fat loss belong in the same conversation. Here is where each one stands, from strongest human evidence to weakest.
FDA-approved for weight loss
Tirzepatide (Zepbound) and semaglutide (Wegovy injection and Wegovy pill). See how they compare in semaglutide vs tirzepatide.
Approved, but for something narrower
Tesamorelin (Egrifta) is approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
Investigational
Retatrutide and CagriSema (cagrilintide plus semaglutide). Available only inside clinical trials.
Research-only
AOD-9604, MOTS-c and 5-Amino-1MQ. Sold as research chemicals, not approved for human use.
The two approved options
Semaglutide and tirzepatide are the only peptides FDA-approved for chronic weight management, and they are the ones with head-to-head data.
In STEP 1, semaglutide 2.4 mg produced 14.9% average weight loss over 68 weeks versus 2.4% on placebo. In SURMOUNT-1, the highest tirzepatide dose produced 20.9% over 72 weeks. Then the two were tested directly against each other.
SURMOUNT-5, 751 adults with obesity, average weight loss at 72 weeks (Aronne et al., NEJM 2025).
Semaglutide is also the first GLP-1 approved as a once-daily weight-loss pill, the Wegovy pill, approved in December 2025. More on tirzepatide's trials in tirzepatide human studies. For current self-pay prices, see how much peptides cost.

What is coming next
Two peptide treatments have finished large trials with results beyond today's approved drugs, but neither is approved yet.
Retatrutide
A triple agonist (GIP, GLP-1 and glucagon) from Eli Lilly. In the Phase 3 TRIUMPH-1 trial, the 12 mg dose produced 28.3% average weight loss at 80 weeks. Lilly has said it plans to file with the FDA in early 2027. Compare it in retatrutide vs tirzepatide.
CagriSema
A weekly combination of cagrilintide (an amylin analog) and semaglutide from Novo Nordisk. In REDEFINE 1, participants lost 20.4% on average over 68 weeks. Novo Nordisk submitted it to the FDA in December 2025, and it is under review.
Anything sold online as "research retatrutide" is not the trial drug and has no quality guarantee. See what research use only means.

Research-only compounds: what the data says
These are heavily marketed for fat loss, but the human evidence is thin or missing. Here is each one in plain terms.
| Compound | What it is | Human evidence for fat loss | Status |
|---|---|---|---|
| AOD-9604 | A fragment of human growth hormone | Six placebo-controlled human trials found it well tolerated, but it was never approved as a weight-loss treatment. | Not approved for any use |
| MOTS-c | A peptide made by mitochondria | None. Metabolic effects come from mouse studies. An FDA advisory committee voted in July 2026 to recommend it for the compounding list for obesity; that vote is not binding. | Not approved, not on the 503A list |
| 5-Amino-1MQ | A small molecule, not a peptide, that blocks the enzyme NNMT | None. One 2018 mouse study. | Not approved |
| Tesamorelin | A growth hormone releasing hormone analog | Reduced abdominal fat in adults with HIV lipodystrophy in trials. Not studied as a general weight-loss drug. | Approved for HIV lipodystrophy only |
For the full regulatory picture, see the FDA peptide status tracker and are peptides legal in 2026.
Lose fat, keep muscle
Some of the weight lost on a GLP-1 is muscle and other lean tissue. How much depends heavily on what you do alongside it.
STEP 1 body-composition substudy, semaglutide 2.4 mg, change over 68 weeks.
Fat dropped about twice as much as lean mass, so body composition improved overall. Resistance training and enough daily protein are the most practical ways to keep more of the muscle. Set your targets with the free fat loss calculator.

What happens when you stop
For most people, the weight returns. These drugs manage appetite while you take them; they do not reset it permanently.
In the STEP 1 extension, people regained about two-thirds of the weight they had lost within a year of stopping semaglutide. In SURMOUNT-4, people switched from tirzepatide to placebo regained 14% of their body weight over the next year, while those who stayed on it lost another 5.5%.
That is why habits built during treatment matter: regular training, protein at each meal and tracking your markers. Upload your bloodwork to Lab Analysis to watch how your metabolic markers change over time.

Plan it with BioStackIQ
Free tools to set targets, organize a plan you have discussed with your clinician, and track how your body responds.
Where to buy
Compare prescription compounding and research-grade sources for the peptides on this page:
Common question: what is Elora?
Elora is eloralintide, Eli Lilly's experimental weekly amylin injection. Read what the eloralintide research shows, including Phase 2 weight loss, side effects and Phase 3 status, or browse more community questions.
Frequently asked questions
What is the best peptide for fat loss?
Based on human trials, tirzepatide currently produces the most weight loss of any FDA-approved option. In the SURMOUNT-5 head-to-head trial, people on tirzepatide lost 20.2% of their body weight over 72 weeks versus 13.7% on semaglutide. Retatrutide produced more in its Phase 3 trial but is still investigational and not FDA-approved. The right choice for any individual is a decision for a prescribing clinician.
Do research peptides like AOD-9604 or MOTS-c work for fat loss?
There is no good human evidence that they do. AOD-9604 was well tolerated in human trials but was never approved for any use. MOTS-c and 5-Amino-1MQ have shown effects only in animal studies, and 5-Amino-1MQ is a small molecule, not a peptide. None of them is FDA-approved.
Are GLP-1 drugs peptides?
Yes. Semaglutide, tirzepatide, retatrutide and cagrilintide are all peptides, which is why they come up in conversations about peptides for weight loss. Semaglutide and tirzepatide are FDA-approved prescription drugs. Retatrutide and the cagrilintide plus semaglutide combination (CagriSema) are not approved yet.
Will I lose muscle on a GLP-1?
Some of the weight lost is lean mass. In a body-composition substudy of the STEP 1 trial, total lean mass fell 9.7% while fat mass fell 19.3% over 68 weeks on semaglutide. Resistance training and adequate protein are the most practical ways to protect muscle while losing weight; discuss targets with your clinician.
What happens when you stop taking semaglutide or tirzepatide?
Most people regain weight. In the STEP 1 extension, participants regained about two-thirds of the weight they had lost within a year of stopping semaglutide. In SURMOUNT-4, people switched from tirzepatide to placebo regained 14% of body weight over the following year, while those who stayed on it lost another 5.5%.
Is there an FDA-approved peptide pill for weight loss?
Yes. The FDA approved the Wegovy pill, an oral form of semaglutide taken once daily, for chronic weight management in December 2025. In its OASIS 4 trial, participants who stayed on treatment lost 16.6% of body weight over 64 weeks, compared with 2.7% on placebo.